pembrolizumab
merck
['keynote,651', 'keynote-651', 'pembrolizumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
moffitt's dr. richard kim presents long-term follow up results of the phase 1b keynote-651 study evaluating pembrolizumab (pembro) plus mfolfox7 or folfiri for metastatic #crc tomorrow at #asco22. view abstract: 
The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. For news and stories visit https://t.co/XaP6iv4q19.